The FDA has approved a new use for AstraZeneca’s Farxiga (dapagliflozin) to reduce risk of cardiovascular death and hospitalisation with heart failure, in adults with reduced ejection ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback